Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction

Robert J Henning

ORCID number: Robert J Henning (0000-0002-6958-4847).

Author contributions: The author finished manuscript alone.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Received: July 12, 2019
Peer-review started: July 17, 2019
First decision: August 2, 2019
Revised: October 17, 2015
Accepted: November 26, 2019
Article in press: November 26, 2019
Published online: January 26, 2020

P-Reviewer: Nurzynska D, Ueda H
S-Editor: Dou Y
L-Editor: A
E-Editor: Zhang YL

Abstract

Nearly six million people in United States have heart failure. Fifty percent of these people have normal left ventricular (LV) systolic heart function but abnormal diastolic function due to increased LV myocardial stiffness. Most commonly, these patients are elderly women with hypertension, ischemic heart disease, atrial fibrillation, obesity, diabetes mellitus, renal disease, or obstructive lung disease. The annual mortality rate of these patients is 8%-12% per year. The diagnosis is based on the history, physical examination, laboratory data, echocardiography, and, when necessary, by cardiac catheterization. Patients with obesity, hypertension, atrial fibrillation, and volume overload require weight reduction, an exercise program, aggressive control of blood pressure and heart rate, and diuretics. Miniature devices inserted into patients for pulmonary artery pressure monitoring provide early warning of increased pulmonary pressure and congestion. If significant coronary heart disease is present, coronary revascularization should be considered.

Key words: Diastolic heart failure; Myocardial stiffness; Incomplete left ventricular relaxation; Echocardiographic heart failure criteria; Pulmonary artery pressure monitoring; Drug treatment

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Three million people in United States have heart failure with normal left ventricular systolic function but abnormal diastolic function due to increased myocardial stiffness. These patients are often elderly women with hypertension, ischemic heart disease, atrial fibrillation, obesity, diabetes mellitus, renal disease, or obstructive lung disease. The annual mortality rate of these patients is 8%-12% per year. The diagnosis is based on history, physical examination, laboratory data, echocardiography, and, when necessary, by cardiac catheterization. These patients often require weight reduction, an exercise program, aggressive control of blood pressure and heart rate, and diuretics. If significant coronary heart disease is present, coronary revascularization should be considered.
INTRODUCTION

Heart failure is a clinical syndrome, characterized by symptoms of breathlessness and easy fatigability, and signs of fluid retention, such as elevated jugular venous pressure, pulmonary crackles, and ankle edema, that result from the impaired ability of the heart to maintain a cardiac output that meets the metabolic needs of the body. Currently, nearly six million people in the United States have heart failure and require 30.7 billion dollars per year for health care[1]. Moreover, the healthcare costs for treating patients with heart failure in the United States are projected to increase to $70 billion in 2030[2].

Approximately 50% of the patients with heart failure have normal, or near-normal left ventricular (LV) systolic heart function with a LV ejection fraction ≥ 50% and a LV end-diastolic volume index < 97 mL/m². These patients are described as having heart failure with preserved ejection fraction (HFpEF). However, these patients have abnormal LV diastolic function with incomplete LV relaxation due to increased myocardial stiffness. This form of heart failure is becoming the dominant form of heart failure among older adults in the United States and in Europe due, in part, to the increasing longevity of the population. By the year 2020, 8% of the United States and European population older than 65 years of age will have HFpEF[3].

Although most physicians have only recently become aware of HFpEF, the first description of HFpEF was in 1966 when “presbycardia” with decreased elasticity of the heart, also known as “senile heart disease”, was first described in elderly individuals[4]. Currently, the most common patients with HFpEF are elderly women with comorbid conditions, such as hypertension with LV hypertrophy (60%-80%), ischemic heart disease (35%-70%) that may be occult, atrial fibrillation (15%-65%), obesity (32%-46%), diabetes mellitus (20%-45%), renal disease (51%-58%), and obstructive lung disease (24%-30%)[5,6]. In addition, women as they age develop greater systemic arterial and LV stiffness than men which results in concentric LV myocardial remodeling and HFpEF.

The systemic arterial and ventricular stiffness in HFpEF is amplified by the coexistence of hypertension, chronic renal disease, and diabetes mellitus. With an increase in arterial stiffness, the pressure wave ejected from the LV is reflected back to the heart, thereby increasing LV afterload, decreasing diastolic ventricular function, and increasing the hydraulic work and myocardial oxygen requirements of the heart. These hemodynamic effects lead to decreased ventricular diastolic function, increased ventricular diastolic filling pressures, decreased coronary flow reserve, and pulmonary vascular congestion. As a result, patients experience shortness of breath.

Heart disease with preserved ejection fraction is a heterogenous syndrome with multiple different conditions that can contribute to the syndrome. Understanding and targeting the pathological conditions that contribute to this syndrome may have greater patient benefit than targeting the final pathway of cardiac dysfunction alone. The specific conditions that can contribute to HFpEF are listed in Table 1 which is adapted in part from[7,8].

Patients who are hospitalized because of HFpEF have complication rates that are similar to those patients with heart failure and reduced ejection fraction (HFrEF), including similar rates of cardiac arrest, acute coronary syndromes, renal insufficiency and failure, and admission to critical care units[9]. Despite similar rates of in-hospital complications in the two groups, patients with HFpEF are less likely to receive cardiology consultation while in the hospital than patients with HFrEF.

Table 2 compares the clinical characteristics of patients with HFpEF with patient with HFrEF and is adapted in part from[10,11].

The annual mortality rate of patients with HFpEF is approximately 8% per year but increases to approximately 10%-12% per year among patients older than 70 years of age[10,11]. The prognosis of patients after the first hospitalization for HFpEF is poor with one-year mortality rates as high as 25% among older patients and five-year mortality rates of 24% to 54%[12]. Thirty percent of the patients with HFpEF die of noncardiac causes, compared with 17% of patients with HFrEF, due to the presence of one or more comorbid conditions. In this regard, the predictors of death among
Table 1 Conditions that contribute to heart failure with preserved ejection fraction

| Condition                                      |
|------------------------------------------------|
| Obesity                                        |
| Hypertension                                   |
| Coronary artery disease                        |
| Atrial fibrillation                            |
| Diabetes mellitus                              |
| Chronic obstructive pulmonary disease          |
| Obstructive sleep apnea                        |
| Anemia                                         |

patients with HFpEF include advanced age, increased systolic blood pressure, atrial fibrillation, a prior cerebral vascular event, renal insufficiency or other major organ dysfunction with sepsis[^14^][^15^].

**PATHOPHYSIOLOGICAL MECHANISMS IN HFpEF**

LV diastolic dysfunction in individuals with HFpEF is characterized by increased diastolic ventricular stiffness, which slows LV relaxation, increases LV diastolic filling pressures and limits cardiac output[^16^][^17^]. Different pathophysiologic mechanisms are hypothesized to contribute individually or in combination to LV diastolic dysfunction in patients with HFpEF. The current hypotheses include: (1) Cardiomyocyte titin hypophosphorylation; (2) Vascular endothelial cell inflammation and dysfunction; (3) Abnormal calcium homeostasis; (4) Increased ventricular matrix formation; and (5) Obesity.

**CARDIOMYOCYTE TITIN HYPOPHOSPHORYLATION**

Resting tension in cardiomyocytes is highly dependent on titin, which is a large sarcomeric protein that functions as a “molecular spring” which stores energy during ventricular contraction and releases energy during ventricular relaxation. Consequently, titin contributes to early myocardial diastolic recoil and late myocardial diastolic distensibility[^18^]. A shift in titin isoform expression from the compliant N2BA to the stiff N2B isoform, hypophosphorylation of the N2B isoform, and lower overall phosphorylation of titin increases the resting tension of cardiomyocytes and contributes to increased LV myocardial stiffness and diastolic dysfunction[^18^-^21^]. Consequently, manipulation of the phosphorylation state of titin and the titin isoforms represents a therapeutic target for the treatment of patients with HFpEF.

**INFLAMMATION**

Obesity, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, and anemia in patients can induce an inflammatory state with increased circulating C reactive protein, interleukin 1 (IL-1) receptor-like 1 protein, growth differentiation factor 15, IL-6, tumor necrosis factor-a, and pentraxin 3[^22^][^23^]. See Figure 1. Inflammation of the coronary microvascular endothelium produces free oxygen radicals and vascular cell adhesion molecules that attract circulating leukocytes to the microvascular which secrete transforming growth factor-β (TGF-β). TGF-β converts myocardial fibroblasts to myofibroblasts, which increase myocardial collagen deposition and cause interstitial fibrosis. Inflammatory free oxygen radicals also reduce nitric oxide (NO) bioavailability, and increase peroxynitrite (ONOO–), which reduces protein kinase G (PKG), which can increase cardiomyocyte stiffness, promote hypophosphorylation of titin, accelerate pro-hypertrophic signaling in cardiac myocytes and enhance diastolic dysfunction[^17^][^21^][^25^].

In addition, systemic inflammation decreases the vasodilator response of the coronary microvascular to acetylcholine and reduces renal blood flow and the ability of the kidneys to excrete sodium and water with resultant progressive expansion of intravascular volume[^1^]. Systemic inflammation also affects the lungs and skeletal muscle by contributing to pulmonary hypertension, muscle weakness and sarcopenia[^1^]. However, therapies to date that reduce systemic inflammation and/or
Table 2  Clinical characteristics of patients with heart failure with preserved ejection fraction and heart failure and reduced ejection fraction

|                  | HFpEF                      | HFrEF                      |
|------------------|----------------------------|----------------------------|
| Sex              | Women (62%)                | Men (60%)                  |
| Age (yr)         | 74                         | 70                         |
| Obesity          | 41.4%                      | 35.5%                      |
| Diabetes mellitus| 45%                        | 40%                        |
| Hypertension     | 77%                        | 69%                        |
| Chronic kidney disease | 56%                  | 45%                        |
| Coronary artery disease | 50%                    | 59%                        |
| Prior myocardial infarction | 24%               | 36%                        |
| LV remodeling    | Concentric                 | Eccentric                 |
| LV ejection fraction | ≥ 50%                   | < 40%                      |
| Atrial fibrillation in hospitalized patients | 65%                     | 53%                        |
| Ventricular dysrhythmias | 3%                       | 11%                        |
| Hospitalizations for heart failure | Increasing         | Decreasing                 |
| Therapies that decrease mortality | None at present time     | Beta-Blockers, ACE inhibitors, biventricular pacemakers, coronary revascularization |

HFpEF: Heart failure with preserved ejection fraction; HFrEF: Heart failure and reduced ejection fraction; LV: Left ventricular.

Cardiomyocyte calcium-handling alterations

High circulating concentrations of the free oxygen radical peroxynitrite in patients with HFpEF increase cardiomyocyte protein phosphatase 2A activity, which decreases cardiomyocyte phospholambam phosphorylation, reduces sarcoplasmic reticulum Ca\(^{2+}\) uptake, and increases cardiomyocyte diastolic cytosolic Ca\(^{2+}\). In addition, abnormal cardiomyocyte sodium-calcium exchange and also calcium leak from the sarcoplasmic reticulum increase cardiomyocyte diastolic cytosolic calcium concentrations, which increases cardiomyocyte resting tension in HFPEF patients due to a delayed inactivation of actin-myosin crossbridges\(^{[26,27]}\). However, reductions in cardiomyocyte calcium overload with ranolazine to date have not significantly improved myocardial relaxation and diastolic dysfunction\(^{[28]}\). Nevertheless, abnormal calcium homeostasis is a potential therapeutic target for the treatment of patients with HFpEF.

Increased extracellular matrix formation

Myocardial biopsies from patients with HFpEF, especially patients with hypertension and HFpEF, show an increase in the collagen volume fraction and an increase in myocardial fibrosis in comparison with patients without heart failure\(^{[29,30]}\). In this regard, inflammation can cause the release of TGF-β from fibroblasts and monocytes/macrophages, which induce the differentiation of fibroblasts into collagen-producing myofibroblasts, while simultaneously decreasing matrix metalloproteinase (MMP)-1 and the tissue inhibitor of (MMP)-1\(^{[17,31,32]}\). In addition, endothelin-1, angiotensin II, platelet-derived growth factor, and connective tissue growth factor govern fibroblast activation/differentiation and represent potential therapeutic targets in the treatment of patients with HFpEF\(^{[33]}\).

Myocardial collagen synthesis can also be increased during the female menopause where decreased circulating estrogen is associated with activation of the renin-angiotensin-aldosterone system\(^{[34]}\). Collagen expansion of the myocardial extracellular matrix, and especially an increase in the collagen type 1 fibers and the amount of crosslinked collagen, has an adverse effect on myocardial mechanical, electrical, and microvascular function and contributes to decreased diastolic function in HFpEF. Myocardial fibrosis also decreases myocardial capillary density, coronary perfusion reserve, and myocardial energy production\(^{[35]}\). Studies of anti-fibrotic agents, such as...
Pirfenidone and also valsartan/sacubitril, in the PIROUETTE trial, the Parallax and the PARAGON-HF trials will help to determine in patients with HFpEF whether significant regression of fibrosis in the myocardium can occur and can be associated with improvement in diastolic ventricular function.

**MICROVASCULAR DYSFUNCTION**

Exercise studies of patients with HFpEF implicate LV stiffness and impaired exercise vasodilation and raise the possibility that the impaired diastolic reserve in these patients may be related to coronary microvascular dysfunction. In an autopsy study of 124 patients with HFpEF compared with 104 age-matched control patients, HFpEF patients had a median of 961 coronary microvessels/mm² vs 1316 vessels/mm² in controls[31,35]. In addition, patients with HFpEF had more severe coronary artery disease with 65% of patients with ≥ 1 coronary vessel with > 50% diameter stenosis versus 13% in controls[34]. The vascular changes in the HFpEF patients were associated with heavier hearts with a median weight of 538 g with 9.6% myocardial fibrosis versus 335 g with 7.1% fibrosis in controls[35]. In addition, the myocardial fibrosis increased with decreasing microvascular density. However, cardiomyocyte size and LV hypertrophy are important determinants of the coronary microvascular density in adults and the role of cardiomyocyte size and LV hypertrophy in the determination of microvascular density in HFpEF requires further investigation.

**OBESITY**

Adipocytes synthesize cell-signaling molecules which include leptin, nerilysin and aldosterone which play a role in systemic inflammatory processes, cardiac fibrosis, and sodium and water retention[36]. In this regard, obesity can lead to cardiac fibrosis and increased ventricular diastolic stiffness through: (1) Leptin secretion from adipose tissue which induces cardiac fibrosis through galectin-3, TGF-β and connective tissue growth factors[37]; (2) Activation of beta2-adrenergic receptors which can enhance the synthesis of proinflammatory cytokines such as IL-6[38]; (3) Increased activity of nerilysin from adipocytes, by degrading endogenous natriuretic peptides promotes plasma volume expansion, loss of the anti-aldosterone action of endogenous natriuretic peptides, and cardiac fibrosis[39]; and (4) Aldosterone secretion, in direct proportion to body mass, which increases collagen synthesis by cardiac fibroblasts[40].

Together these mechanisms can cause myocardial fibrosis and also cause sodium...
retention with plasma volume expansion. In addition, increased intramuscular fat decreases the supply of oxygen to working muscles and can impair oxidative metabolism in the skeletal musculature and, in this manner, contributes to the decreased functional capacity experienced by patients with HFrEF[5,41]. Figure 1 summarizes the different factors that can contribute to HFrEF.

**DIAGNOSIS**

The diagnosis of HFrEF in patients is based on the history, the physical examination, the laboratory data, the echocardiogram, and, when necessary, by cardiac catheterization.

The chest radiograph in patients with HFrEF often shows the presence of cardiomegaly and also evidence of pulmonary congestion. The electrocardiogram shows nonspecific ST-T wave changes although ECG evidence of myocardial ischemia or prior myocardial infarction may be present. Atrial fibrillation is frequently present on the ECG[42]. Plasma brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) are often mildly increased with BNP > 100 pg/mL or NT-proBNP > 300 pg/mL. The concentrations of these peptides are less than the concentrations in patients with HFrEF[43]. Nevertheless, a BNP measurement > 100 pg/mL or a NT-proBNP > 300 pg/mL are independent predictors of adverse cardiovascular events in patients with HFrEF[44]. Currently, the measurements of natriuretic peptides and troponins are recommended for the diagnosis and the prognosis of patients with heart failure, and the measurements of suppression of tumorgenicity 2, a marker of systemic inflammation, and galectin-3, a marker of cardiac fibrosis, are recommended for additional patient risk stratification and prognosis[45,46].

Echocardiography is a very useful noninvasive technique in the diagnosis of patients with HFrEF and often demonstrates the presence of LV hypertrophy or concentric LV remodeling with a LVEF that is ≥ 50% and a LV volume index that is < 97 mL/m². Left atrial enlargement is oftentimes present with a left atrial volume index > 34 mL/m² in patients who are not in atrial fibrillation. Common echocardiographic indices of significant diastolic dysfunction are listed in Table 3 which is adapted in part from[47-49].

However, echocardiographic determined E/A and E/e’ ratios should not be used in isolation in assessing patients, but rather the ratios should be used in conjunction with the patient’s clinical characteristics and laboratory data to accurately diagnose LV diastolic dysfunction and HFrEF[49]. In this regard, echocardiographic studies of 745 patients with HFrEF in the I-PRESERVE study reported that the LV end-diastolic volume was within normal limits in > 95 percent of the patients, LV hypertrophy or concentric remodeling was present in 50 to 60 percent, LV diastolic dysfunction (mild to severe) was present in > 70 percent, and left atrial area enlargement was present in > 65 percent of patients[50].

Recently a scoring system has been developed to facilitate the diagnosis of HFrEF in patients with dyspnea and distinguish these patients from patients with non-cardiac causes of dyspnea[51]. The scoring system uses 6 clinical and echocardiographic characteristics (H2FPEF: Heavy, Hypertension, Atrial Fibrillation, Pulmonary Hypertension, Elderly, LV filling Pressure) that are obtained in the evaluation of patients with unexplained exertional dyspnea to determine the probability of HFrEF. Patients with score high s of 6 to 9 have a probability of HFrEF > 90%. Conversely, patients with low scores of 0 to 1 have a probability of HFrEF ≤ 23%. Patients at intermediate probability with H2FPEF scores of 2 to 5 require additional testing to determine the cause of dyspnea. Table 4 lists the H2FPEF scoring system and is adapted from[52].

**CARDIAC MAGNETIC RESONANCE (CMR)**

In patients with HFrEF, the myocardial extracellular matrix can be determined with CMR T1 mapping and is a predictor of LV myocardial stiffness and LV diastolic dysfunction. Excessive extracellular matrix deposition is a major contributor to the impaired cardiac relaxation and cardiac stiffness that are the hallmarks of HFrEF. Moreover, the CMR detection of myocardial extracellular matrix can precede the clinical diagnosis of HFrEF and correlates with patient myocardial biopsy specimens and hospitalizations for heart failure or death from cardiovascular causes[53-56].

In 410 patients with HFrEF or at risk for HFrEF, CMR determinations of increased myocardial extracellular volume (ECV) as an estimate of myocardial fibrosis were strongly associated with hospitalizations for heart failure or death during the
Table 3  Echocardiographic indices of diastolic dysfunction

1. The ratio of the mitral blood flow velocity into the LV in early diastole (the E wave) to peak blood flow velocity in late diastole caused by atrial contraction (the A wave), or the E/A ratio, ≥ 2. The normal E/A is approximately 0.8. However, tachycardia, atrioventricular block, and left bundle branch block can lead to fusion of E and A waves, and ambiguity in diastolic function assessment.

2. Increased left atrial pressure measured by early mitral blood flow velocity across the mitral valve (E wave) to the early diastolic velocity (e') of the lateral mitral annulus, or E/e' ratio. An E/e' ratio 10 = mild and E/e' ratio > 14 = significant LV dysfunction. If the lateral mitral annulus e' velocity is not quantifiable, the septal mitral annular e' velocity can be used. In this case, the E/e' is increased if the ratio is > 15.

3. Lateral mitral annular e' velocity < 10 cm/s or septal e' mitral annular velocity < 7 cm/s.

4. Pulmonary artery systolic pressure > 35 mmHg indicative of pulmonary arterial hypertension. Pulmonary artery systolic pressure = 4 × (peak tricuspid regurgitation velocity)^2 + estimated right atrial pressure. These criteria should not be used in patients with significant pulmonary disease.

5. An echocardiographic determination of global longitudinal strain of -16.05 ± 2.16. This measurement can separate patients with HFpEF from patients with hypertension and normal controls in whom the global longitudinal strain measurements are -18.58 ± 2.84 and -19.59 ± 1.49, respectively.

HEART CATHETERIZATION

For patients for whom the probability of HFpEF remains intermediate after history, physical examination, natriuretic peptide determinations, and echocardiography have been performed, invasive hemodynamic assessment of cardiac filling pressures, with provocative stress maneuvers such as exercise, is useful to make or exclude the diagnosis of HFpEF.

Right heart catheterization

Many patients with HFpEF have normal right and LV end-diastolic pressures at rest, when measured either invasively or non-invasively. In these patients, right heart catheterization measurements of pulmonary artery wedge pressure, cardiac output, and oxygen extraction during exercise are valuable tools in the diagnosis of patients with dyspnea due to HFpEF. During submaximal exercise, patients with HFpEF display pulmonary artery wedge pressures > 25 mmHg or an increase of 7 ± 3 mm Hg above the resting measurement, and pulmonary artery systolic pressures ≥ 45 mmHg in contrast to patients with noncardiac dyspnea. With exercise, older patients with HFpEF demonstrate a marked rise in arteriovenous oxygen content difference of 10.8 ± 1.8, driven by enhanced oxygen extraction, and lower increments in cardiac output in comparison with younger patients with HFpEF. This is especially true in older women who have small LV chambers and rely on heart rate increases to meet the cardiac output demands of exercise.

Left heart catheterization and coronary artery angiography

Community-based studies show that coronary heart disease (CAD) is common in HFpEF, and is present in 40% to 60% of patients with HFpEF. Patients with CAD are more likely to be men and to have CAD risk factors, including hypertension, diabetes, hyperlipidemia, and tobacco use. However, symptoms of angina and heart failure are similar in patients with and without CAD, as are measures of cardiovascular structure, function, and hemodynamics. Nevertheless, HFpEF patients with CAD experience a fourfold greater decline in EF over time compared with patients without CAD. The presence of CAD is associated with worse outcome in HFpEF, which appears to be independent of other predictors. In a study of elderly patients with a mean age of 72 years, patients with HFpEF and CAD have a 1-2-year mortality rate of 20%. In these patients, coronary revascularization is associated with a decrease in mortality and with outcomes that are not different from patients

HFpEF: Heart failure with preserved ejection fraction.
Table 4 Heart failure preserved ejection fraction scoring system: Heart failure with preserved ejection fraction

| Clinical characteristic                  | Clinical measurement                                      | Points awarded |
|-----------------------------------------|----------------------------------------------------------|----------------|
| Heavy                                   | Body mass index > 30 kg/m²                                | Two            |
| Hypertension                            | Two or more hypertensive medications                      | One            |
| Atrial fibrillation                     | Paroxysmal or persistent                                 | Three          |
| Pulmonary hypertension by echocardiogram| Pulmonary artery systolic pressure > 35 mmHg              | One            |
| Elderly                                 | Age > 60 yr                                               | One            |
| LV filling pressure by echocardiogram   | Echocardiographic e/e' > 9                                | One            |

with HFpEF without CAD. Consequently, patients with HFpEF should be subcategorized according to the presence or absence of CAD. If significant coronary artery disease is present, the patients should be evaluated for coronary revascularization.

TREATMENT

Patients with HFpEF and major obstructive coronary artery disease should be treated with coronary artery revascularization. In addition, since many hospitalizations and deaths in patients with HFpEF are due to noncardiovascular causes such as chronic obstructive lung, chronic kidney disease, and diabetes, these disorders must be identified early in the clinical course and aggressively treated. In patients with NYHA class II and III heart failure and iron deficiency (ferritin < 100 ng/mL or 100 to 300 ng/mL if transferrin saturation is < 20%), intravenous iron replacement is reasonable to improve functional status and quality of life.

GENERAL TREATMENT OF PATIENTS WITH HFpEF WITH OBESITY, HYPERTENSION, AND ATRIAL FIBRILLATION

Medical treatment in HFpEF patients with non-obstructive coronary artery disease includes weight reduction and control of blood pressure, heart rate, and fluid status. More than 80% of patients with heart failure with HFpEF, are overweight or obese and deconditioned. A caloric restriction diet is feasible and safe in older, obese patients with HFpEFs, and significantly improves patient dyspnea, peak oxygen consumption, and quality of life. Caloric restriction combined with endurance exercise, such as walking exercise for one hour three or more times per week, is additive and the combination can produce a 2.5 mL/kg/min increase in peak oxygen consumption and an increase in exercise capacity. Exercise training, such as can occur with a cardiac rehabilitation program, can also improve the maximum heart rate and the diastolic function of the LV as measured by the echocardiographic ratio of early to late mitral valve filling (E/A ratio) and the LV filling pressure E/e’ ratio.

Moreover, a decrease in body weight and an increase in peak oxygen consumption is strongly correlated with a decrease in the systemic biomarkers of inflammation in the body and is primarily attributable to increased peripheral microvascular and skeletal muscle function.

Fifty-one percent of patients with HFpEF have hypertension, whereas among patients with HFrEF, hypertension is present in 41%. In a meta-analysis of 123 studies with 613815 hypertensive patients, a 10 mmHg decrease in systolic BP reduced the risk of heart failure complications by 28%, independently of the baseline BP or co-morbidity status. In this regard, diuretic drugs are effective for blood pressure control and for the prevention of volume overload. Analysis from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (Allhat) Trial found that the diuretic chlorthalidone reduced the risk of HFpEF and the incidence of HFpEF hospitalizations among high-risk hypertensive patients when compared with lisinopril, amlodipine, and doxazosine. For patients whom are persistently hypertensive despite diuretic therapy, renin-angiotensin-aldosterone inhibition with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker are recommended for reduction in the blood pressure to ≤ 130/80 mmHg. In addition, mineralocorticoid antagonists, such as spironolactone or eplerenone, can play an important role in treatment of patients with HFpEF by limiting aldosterone, which is a volume retention and profibrotic hormone, and blood pressure. In the
Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial, spironolactone reduced patient hospitalizations for heart failure, reduced the composite end-point of cardiovascular death, heart failure hospitalization, and aborted cardiac arrest in patients from the Americas but not patients from Russia and Georgia[70]. Furthermore, two recent retrospective studies report that the long-term treatment with a mineralocorticoid antagonist, such as spironolactone or eplerenone, and a beta-adrenergic receptor blocker drugs is associated with a reduction in the incidence of new-onset HFpEF in patients with hypertension[71,72]. Consequently, the effective control of vascular volume and blood pressure in hypertensive patients can prevent patient progression to symptomatic HFpEF. However, while diuretics and antihypertensive medications can be effective in bringing about symptomatic relief, care must be taken to avoid hypotension and azotemia in patients with HFpEF.

Atrial fibrillation is present in 15% to as many as 41% of patients with HFpEF[73,74]. The arrhythmia may be associated with increased fatigue and exertional intolerance, natriuretic peptide elevation, left atrial remodeling and an increase in the risk of death[75,76]. The treatment includes identification and treatment of the causes of atrial fibrillation, such as poorly controlled hypertension, obstructive sleep apnea, diabetes mellitus, or thyrotoxicosis. Patients with atrial fibrillation, HFpEF, and sleep apnea should undergo a sleep study in order to determine whether the sleep apnea is predominantly obstructive or central in nature and patients with obstructive sleep apnea treated with continuous positive airway pressure[46,76]. Anticoagulation is recommended for patients with a CHA2DS2 VAS score ≥ 2. Beta-adrenergic receptor blocking drugs or non-dihydropyridine calcium channel blocking drugs, such as verapamil or diltiazem, are suggested for rate control. Experience with atrial catheter ablation of atrial fibrillation in patients with HFpEF is limited. In a small, single center study, catheter ablation of atrial fibrillation improved diastolic function in patients who maintained sinus rhythm[77]. Additional investigations of catheter ablation of atrial fibrillation in patients with HFpEF are necessary.

Recent clinical trials of sodium glucose cotransporter-2 inhibitors have shown promising effects on heart failure outcomes in patients with heart failure and diabetes mellitus. In the EMPA-REG Cardiovascular Outcome Event Trial in patients with type 2 diabetes mellitus, the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin was associated with a reduction in major adverse cardiovascular endpoints and a significant reduction in heart failure hospitalizations[78]. SGLT2 inhibitors, such as empagliflozin, promote glycosuria and diuresis by reducing glucose and sodium absorption in the proximal renal tubule, without activating the sympathetic nervous system. SGLT2 inhibitors also appear to decrease markers of inflammation[79]. Additional studies of SGLT2 inhibitors in patients with HFpEF and diabetes mellitus are in progress.

In summary, inhibitors of the sympathetic nervous and renin-angiotensinaldosterone systems should be considered in patients with HFpEF who have coronary artery disease, hypertension, and atrial fibrillation[80,81]. Sodium glucose cotransporter-2 inhibitors should be considered in patients with HFpEF and type 2 diabetes mellitus[82]. Patients with major obstructive coronary artery disease that contributes to heart failure should be evaluated for coronary artery revascularization[80,81].

### Table 5  Survival after cardiac magnetic resonance determined extracellular volume determination

| CMR ECV          | Year one | Year two | Year three | Year four |
|------------------|----------|----------|------------|-----------|
| ECV < 25%        | 95.8%    | 95.8%    | 95.8%      | 82.1%     |
| 25% ≤ ECV < 30%  | 95.5%    | 90.5%    | 87.6%      | 81.1%     |
| 30% ≤ ECV < 35%  | 88.0%    | 77.3%    | 69.6%      | 65%       |
| 35% > ECV < 40%  | 82.2%    | 74.3%    | 69.4%      | 61.7%     |
| ECV ≤ 40%        | 40.0%    | 40.0%    | 40.0%      | 40.0%     |
| Cardiac amyloid  | 47.1%    | 23.5%    | 0%         | 0%        |

CMR: Cardiac magnetic resonance; ECV: Extracellular volume.
GENERAL PHARMACOLOGY TREATMENT OF PATIENTS WITH HFpEF

The pharmacologic therapy trials for LV dysfunction in patients with HFpEF with beta-adrenergic receptor blockers, calcium channel blocking agents, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and nitrates are not consistent and, in general, have been neutral in decreasing patient mortality. This is, in part, due to differences in trial design and patient population heterogeneity with differences in heart failure etiologies or stages of disease. Recently, patients with LV ejection fractions between 41% and 49% have been categorized as heart failure with mid-range ejection fraction. Patients in this intermediate category match a phenotype that is closer to the clinical profile of HFrEF and have a higher risk of sudden cardiac death and cardiovascular death than patients with HFpEF. Table 6 lists the major pharmacologic studies that have been performed in patients with HFpEF and patients with heart failure with mid-range ejection fraction. Table 6 is adapted, in part, from [80].

MEDICAL DEVICES

Patients with HFpEF and chronotropic incompetence are currently being tested with rate-adaptive atrial pacing (government trial NCT02145351). Patients with HFpEF can have normal resting left atrial pressures but develop marked increases in left atrial pressures and pulmonary hypertension with exercise due to a decrease in LV diastolic compliance. This is typically manifested as exertional dyspnea. Innovative medical devices, listed below, inserted into patients with HFpEF in clinical trials have shown some promise in improving patient symptomatology.

INTERATRIAL SEPTOSTOMY

An 8 mm unidirectional interatrial left to right shunt device in patients with HFpEF has been investigated to reduce left atrial pressure by 3 to 11 mmHg and provide symptomatic patient relief from dyspnea that is due to increased pulmonary venous pressure. In a randomized Reduce-Left Atrial Pressure in Heart Failure Trial I in 39 patients, the decrease in pulmonary wedge pressure during exercise and the improvement in workload corrected pulmonary capillary wedge pressure, exercise duration, and peak exercise workload compared to sham controls were numerically better in the treatment group but the differences from controls did not achieve statistical significance [106,110]. A larger trial (REDUCE LAP-HF II Governmental Trial NCT03088033) is currently examining the effects of an interatrial septal device on clinical outcomes and quality of life. The long term effects of volume loading with this device and similar devices, such as the V Wave device (Governmental Trial NCT02511912) and the Atrial Flow Regulator (Governmental Trial NCT03030274), on right heart chambers and function, the pulmonary circulation, the cardiac rhythm, and the potential for paradoxical embolism in older patients who typically have HFpEF, require further investigation.

PULMONARY ARTERY PRESSURE MONITORING

The CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) Trial was a prospective, randomized controlled trial that investigated whether medical treatment based on daily pulmonary artery pressure monitoring would significantly reduce hospitalizations for heart failure treatment [89]. A 15 mm electromechanical pressure sensor was permanently implanted by right heart catheterization into a branch of the right pulmonary artery of each patient and transmitted pulmonary artery pressures by radio signals to an internet web-based system that notified the patient’s physician if the daily pulmonary pressure measurements were outside of a defined range. After 17.6 mo of follow-up, the hospitalization rate was 50% lower in patients where medical treatment decisions were made based on the pulmonary artery pressure measurements [111]. Hemodynamic-guided management using PA pressure measurements appears to be a successful strategy to improve the outcome of patients with HFpEF. More recently, the HEMODYNAMICALLY GUIDED MANAGEMENT OF HEART FAILURE (Guide-HF Governmental Trial NCT03387813) Trial is examining the effects of pulmonary artery pressure monitoring on patient mortality.
| Ref.                                      | Drug vs control | Drug half-life hours | Number patients | Duration | LVEF          | Results                                                                                                                                                                                                 |
|------------------------------------------|-----------------|---------------------|------------------|----------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Swedish Heart Failure Registry[81]       | All BBs (prescribed at discharge) | 6-h Atenolol; 12-19 h Nevibolol | 8244            | 755 d    | LVEF 49%-50% and LVEF > 50% | β-blockers decreased mortality but not combined all-cause mortality or hospitalizations                                                                                                         |
| SWEDIC Trial[82]                         | Carvedilol      | 6-10 h              | 97               | 6 mo     | LVEF ≥ 40%    | E/A ratio improved but no other measures of diastolic function                                                                                                                                               |
| J-DHF Trial[83]                          | Carvedilol      | 6-10 h              | 245              | 38 mo    | LVEF ≥ 40%    | Standard dose, but not low dose, carvedilol reduced; CV mortality and hospitalizations                                                                                                                     |
| COHERE Registry[84]                      | Carvedilol      | 6-10 h              | 4280             | 12 mo    | LVEF > 40%    | Carvedilol had no mortality benefit but decreased hospitalization                                                                                                                                         |
| SENIORS[85,86]                            | Nebivolol       | 2.5-20 h            | 643              | 21 mo    | LVEF > 35%    | Nebivolol did not decrease CV hospitalizations or mortality                                                                                                                                               |
| ELANDD Trial[87]                         | Nebivolol       | 2.5-20 h            | 116              | 21 mo    | LVEF ≥ 45%    | Nebivolol did not increase exercise capacity                                                                                                                                                               |
| CIBIS-ELD Trial[88]                      | Bisoprolol vs Carvedilol | 9-12 vs 6-10 h   | 250             | 3 mo     | LVEF ≥ 45%    | Bisoprolol and carvedilol had no effect on established and prognostic markers of diastolic function                                                                                                         |
| El-Refai et al[89]                       | Beta Blocker (bisoprolol, carvedilol, metoprolol, labetalol, and atenolol) | 6-7 h (Atenolol); 9-12 h (Bisoprolol) | 741       | 25 mo    | LVEF ≥ 50%    | Beta blockers decreased mortality and HF hospitalizations                                                                                                                                             |
| β-PRESERVE[90]                           | Metoprolol succinate vs control | 3-9 h             | 1200            | 24 mo    | LVEF ≥ 50%    | Trial Results not available                                                                                                                                                                                |
| OPTIMIZE-HF[91]                           | All BBs (prescribed at discharge) | 6-7 h Atenolol 12-19 h Nevibolol | 21149       | 3 mo     | LVEF 40%-49% and ≥ 50% | Beta blockers had no effect on mortality and rehospitalization                                                                                                                                           |
| Calcium channel blockers                  | Verapamil vs placebo | 4.5-12 h          | 20               | 1 mo     | LVEF ≥ 45%    | Verapamil increased exercise capacity. Clinicoradiographic score. No change in LVEF.                                                                                                                     |
| Setaro et al[92]                          | Verapamil vs placebo | 4.5-12 h          | 15               | 3 mo     | Normal LVEF   | Verapamil increased exercise time and LV diastolic function                                                                                                                                              |
| Hung et al[93]                            | Verapamil vs placebo | 4.5-12 h          | 20               | 1 mo     | LVEF ≥ 45%    | Verapamil increased exercise capacity. Clinicoradiographic score. No change in LVEF.                                                                                                                     |
| ACE inhibitors                            | Enalapril vs control (diuretics alone) | 11 h             | 21               | 3 mo     | LVEF ≥ 50%    | Enalapril increased exercise time and LVEF                                                                                                                                                               |
| Aronow et al[94]                          | ACE inhibitor (perindopril) vs placebo | 3-10 h with prolonged terminal elimination | 207       | 12 mo    | LVEF ≥ 45%    | Perindopril increased 6 min walk distance but did not decrease mortality                                                                                                                              |
| PEP-CHF trial[95]                         | Irbesartan vs placebo | 11-15 h          | 4563             | 24 mo    | LVEF ≥ 45%    | No decrease in hospitalization or mortality                                                                                                                                                              |
| Trial Description                                                                 | Treatment 1                 | Treatment 2                 | Duration | Follow-up | LVEF Requirement | Main Findings                                                                 |
|---------------------------------------------------------------------------------|-----------------------------|-----------------------------|----------|-----------|------------------|-----------------------------------------------------------------------------|
| **CHARM-Preserved**[^2^] (ACE Inhibitor, BB, CCB)                                | Candesartan vs control     | 9 h                         | 3023     | 37 mo     | LVEF ≥ 40%        | Candesartan slightly decreased hospitalizations but did not decrease mortality |
| Angiotensin receptor blocker/ nephrilysin inhibitors                              |                             |                             |          |           |                  |                                                                             |
| **PARAMOUNT Trial**[^9^]                                                         | Sacubitril/valsartan vs     | 11.5 h                      | 301      | 3 and 8-9 mo| LVEF ≥ 45%        | Sacubitril Valsartan reduced NT-proBNP                                    |
| **PARAGON-HF Governmental Trial NCT01920711**                                    | valsartan                   |                             | 4300     | 57 mo     | LVEF ≥ 45%        | Sacubitril/valsartan not superior to valsartan alone in decreasing hospitalization or cardiovascular mortality |
| **Ivabradine**                                                                   | Ivabradine vs placebo       | 11 h                        | 61       | 7 d       | LVEF ≥ 50%        | Ivabradine increased exercise time, peak oxygen uptake, and decreased E/e’  |
| **EDIFY trial[^1^]**                                                             |                             |                             | 179      | 8 mo      | LVEF ≥ 45%        | No improvement in 6 min walk, E/e’, or NT-proBNP                           |
| **Statins**                                                                      |                             |                             |          |           |                  |                                                                             |
| **Fukuta et al[^10^]**                                                           | Standard HF therapy with    | 2 h (lovastatin)-19 h (rosuvastatin) | 137      | 21 mo     | LVEF ≥ 50%        | Statin therapy associated with reduced mortality                          |
| **Ouzounian et al[^11^]**                                                         | a statin vs without a statin |                             |          |           |                  |                                                                             |
| **Animal model of heart failure (rats)^[^1^][^2^]                                 | Standard HF therapy with    | 19 h                        | 46       | 19 mo     | Preserved EF      | Statins had no benefit                                                     |
| **Digoxin (DIG) trial[^12^]**                                                     | Sildenafil vs placebo       | 3-4 h                       | 216      | 24 mo     | LVEF ≥ 50%        | No improvement in 6 min walk distance, clinical status, or peak O\textsubscript{2} consumption |
| **Phosphodiesterase-5 inhibitors**                                               |                             |                             |          |           |                  |                                                                             |
| **RELAX trial[^13^]**                                                            |                             |                             |          |           |                  |                                                                             |
| **Nitrates**                                                                     |                             |                             |          |           |                  |                                                                             |
| **NEAT-HFpEF trial[^14^]**                                                       | Isosorbide mononitrate vs   | 2.5-5.1 h                   | 110      | 22 mo     | LVEF ≥ 50%        | No improvement in 6 min walk distance or NT-proBNP                          |
| **INDIE-HFpEF[^15,^16^]**                                                        | placebo                     |                             |          |           |                  |                                                                             |
| **Governmental trial NCT02840799**                                               | Oral KNO3 vs KCL            | 1.2 h                       | 26       | 1 mo      | LVEF ≥ 50%        | KNO3 trial is in progress                                                  |

LVEF: Left ventricular ejection fractions; HF: Heart failure; EF: Ejection fraction.

from heart failure.

**MECHANICAL CIRCULATORY ASSISTANCE**

For patients with severe refractory HFpEF in whom medical therapies have provided
no benefit, mechanical circulatory support is being investigated to decrease LV filling pressures and pulmonary congestion and increase cardiac output. In this regard, a partial mechanical circulatory microdevice, which is inserted with a minimally invasive approach, directs blood from the left atrium into the subclavian artery. This system is reported to decrease pulmonary and left atrial pressures in patients with HFpEF. However, patients with HFpEF have small LV dimensions and further decreases in LV stroke volume may limit patient coronary and cerebral blood flow. Additional investigations are needed to evaluate whether this invasive therapy decreases patient morbidity and mortality.

**FUTURE PERSPECTIVES**

The specific etiologies of HFpEF, the mechanisms, the clinical manifestations, and the contributions of comorbidities to the morbidity and mortality of HFpEF must be fully identified in patients. Such identifications will be facilitated by the pursuit of clinical registries and large clinical trials that focus on collecting clinical, imaging, laboratory, and outcome data and treatments. Successful pursuit of these goals will ultimately permit the development of specific drugs and medical devices that will decrease the morbidity and mortality of HFpEF in patients.

**SUMMARY**

The American College of Cardiology, the American Heart Association and the Heart Failure Society recommend the following treatments for patients with HFpEF and symptoms and signs of heart failure (adapted from [46,113]):  
(1) Treatment of hypertension in all HFpEF patients with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers or beta-adrenergic receptor blocking drugs;  
(2) Treatment of patients with HFpEF with volume overload with diuretics;  
(3) In patients with HFpEF with increased BNP, creatinine < 2.5 mg/dL, glomerular filtration rate > 30 mL/min and potassium < 5 mEq/L, treatment with an aldosterone antagonist;  
(4) Control of heart rate with medications in patients with atrial fibrillation;  
(5) In patients with HFpEF and type 2 diabetes mellitus, treatment with a SGLT-2 inhibitor such as Empaglifozin should be considered; and  
(6) Treatment of patients with symptomatic obstructive coronary artery disease and myocardial ischemia that contributes to heart failure with coronary revascularization.

**HFpEF BULLET POINTS**

**Introduction**

Currently, 5.7 million people in the United States have heart failure and require 30.7 billion dollars per year for health care and medications.

50% of patients with heart failure have normal, or near-normal LV systolic heart function but abnormal LV diastolic function with incomplete LV relaxation due to increased myocardial stiffness. These patients have HFpEF.

The most common patients are elderly women with hypertension, ischemic heart disease, atrial fibrillation, obesity, diabetes mellitus, renal disease, or obstructive lung disease.

Patients who are hospitalized because of HFpEF have complication rates that are similar to those patients with HFrEF.

The annual mortality rate of patients is approximately 8% per year but increases to approximately 10%-12% per year among patients older than 70 years of age.

**Pathophysiological mechanisms in HFpEF**

Current hypotheses include:  
(1) Cardiomyocyte titin hypophosphorylation;  
(2) Vascular endothelial cell inflammation and dysfunction;  
(3) Abnormal calcium homeostasis;  
(4) Increased ventricular matrix formation; and  
(5) Obesity.

**Clinical manifestations/diagnosis**

The diagnosis is based on the patient’s history and physical examination with the assistance of laboratory data, echocardiography, and, when necessary, by cardiac catheterization.

A scoring system facilitates the diagnosis of HFpEF in patient with dyspnea and distinguish these patients from patients with non-cardiac causes of dyspnea.

In patients with HFpEF, the myocardial extracellular matrix can be determined
with CMR T1 mapping and is a predictor of LV myocardial stiffness, LV diastolic dysfunction, and patient outcome.

**HFpEF treatment**

Since many hospitalizations and deaths in patients with HFpEF are due to non-cardiovascular causes such as chronic obstructive lung, chronic kidney disease, and diabetes, these disorders must be identified early and aggressively treated.

Patients with obesity, hypertension, and atrial fibrillation require weight reduction, an exercise program, and aggressive control of blood pressure and heart rate.

Patients with volume overload should be treated with diuretics.

Pharmacologic therapy trials with beta-adrenergic receptor blockers, calcium channel blocking agents, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and nitrates have, in general, been neutral in decreasing patient mortality.

Medical treatment based on pulmonary artery pressure monitoring with a permanently implanted right pulmonary artery microsensor significantly reduces hospitalizations for treatment of heart failure. A clinical trial is currently examining the effects on patient mortality from heart failure.

If significant coronary artery disease is present and contributes to heart failure, the patient with HFpEF should be evaluated for coronary revascularization.

**REFERENCES**

1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O’Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguecz CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Munter P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association. Circulation 2018; 137: 667-706 [PMID: 29386208]

2. Heldermanlich PA, Trogdon JG, Khavjou OA, Bueller J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Oremstein D, Wilson PW, Woy JJ; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Critical Care; Perioperative and Reuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-944 [PMID: 21262990 DOI: 10.1161/CIR.0b013e31820a55f5]

3. van Heerebeek L, Paulus WJ. Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J 2016; 24: 227-236 [PMID: 26909795 DOI: 10.1007/s12471-016-0810-1]

4. Dock W. How some hearts age. JAMA 1966; 195: 442-444 [PMID: 5951836 DOI: 10.1001/jama.1966.03310060082024]

5. Nanayakkara S, Patel HC, Kaye DM. Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clin Med Insights Cardiol 2018; 12: 1179546817751609 [PMID: 29343997 DOI: 10.1177/1179546817751609]

6. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005; 112: 2254-2262 [PMID: 16203909 DOI: 10.1161/CIRCULATIONAHA.105.541076]

7. Gazewood JD, Turner PL. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management. Am Fam Physician 2017; 96: 582-588 [PMID: 29094857]

8. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 2009; 119: 3070-3077 [PMID: 19560115 DOI: 10.1161/CIRCULATIONAHA.108.815944]

9. Bhatia RS, Tu JV, Lee DS, Autilin PC, Fang J, Haoeri A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269 [PMID: 16855266 DOI: 10.1056/NEJMoa051530]

10. Rogers FJ, Gundala T, Ramos JE, Serajian A. Heart Failure With Preserved Ejection Fraction. J Am Osteopathic Assoc 2015; 115: 432-442 [PMID: 26111131 DOI: 10.7556/jaoa.2015.089]

11. Quiróz R, Doros G, Shaw P, Liang CS, Gauthier DF, Sam F. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol 2014; 113: 691-696 [PMID: 24484062 DOI: 10.1016/j.amjcard.2013.11.014]

12. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387-1393 [PMID: 11901053 DOI: 10.1161/01.CIR.102.105298]

13. Sharai Z, Zarbasi W. Diastolic heart failure: predictors of mortality. Cardio J 2011; 18: 222-232 [PMID: 21669011]

14. Doury P. Autochthonous anguilluliasis in France. Bull Soc Pathol Exot 1995; 88: 116 [PMID: 8353469 DOI: 10.1016/j.ijcard.2007.12.059]

15. Krittanawong C, Yue B, UIH, Virk H, Zhang HJ, Haider S, Kitui T, Tang W. A Contemporary Analysis
of Predictors of Mortality in Patients With Heart Failure and Preserved Ejection Fraction From the National Inpatient sample. *Circulation* 2018; 136: A12243

16 Zile MR, Baico CF, Gauch WH. Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med* 2004; 350: 1953-1959 [PMID: 15128893 DOI: 10.1056/NEJ Moa03256]

17 Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tšihöpö C. Role of left ventricular stiffness in heart failure with normal ejection fraction. *Circulation* 2008; 117: 2051-2060 [PMID: 18413502 DOI: 10.1161/CIRCULATI O-NAHIA.107.716856]

18 Lewis GA, Schellert EB, Williams SG, Cunningham C, Ahmed F, McDonagh TA, Miller CA. Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. *J Am Coll Cardiol* 2017; 2180-2200 [PMID: 29050567 DOI: 10.1016/j.jacc.2017.09.006]

19 Linke WA, Hamdani N. Giantic business: title N-Gerties and function through and thin. *Circ Res* 2014; 114: 1052-1068 [PMID: 24627729 DOI: 10.1161/CIRCRESAHA.114.301266]

20 Borbély A, Falcao-Pires I, van Heerebeek L, Hamdani N, Eides I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, van der Velden J, Stienen GJ, Paulus WJ. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. *Circ Res* 2009; 104: 780-786 [PMID: 19179267 DOI: 10.1161/CIRCRESAHA.108.193326]

21 van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begienemann MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. *Circulation* 2012; 126: 830-839 [PMID: 22866328 DOI: 10.1161/CIRCULATIONAHA.111.076757]

22 Collier P, Watson CI, Yoon Y, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Leklidge MT, McDonald KM. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? *Eur J Heart Fail* 2011; 13: 1087-1095 [PMID: 21719449 DOI: 10.1093/eurjhf/hfr079]

23 Shah KB, Kop WJ, Christenson RH, Dieercks DB, Henderson S, Hanson K, Li SY, deFilippi CR. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. *Clin Chem* 2011; 57: 874-882 [PMID: 21515743 DOI: 10.1373/clinchem.2010.159277]

24 Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Obha K, Matsuzyawa Y, Akiyama E, Yamamoto E, Sakamoto K, Nagayoshi Y, Kaikita K, Sumida H, Kim-Mitsuayana S, Ogawa H. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. *J Am Coll Cardiol* 2011; 57: 861-869 [PMID: 21310324 DOI: 10.1016/j.jaccardi.2011.06.380]

25 Zuo L, Chuang CC, Hemmelgarn BT, Best TM. Heart failure with preserved ejection fraction: Defining the function of ROS and NO. *J Appl Physiol (1985)* 2015; 119: 944-951 [PMID: 25977452 DOI: 10.1152/japplphysiol.01149.2014]

26 Runte KE, Bell SP, Selby DE, Häßler TN, Ashikaga T, LeWinter MM, Palmer BM, Meyer M. Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction. *Circ Heart Fail* 2017; 10 [PMID: 28784668 DOI: 10.1161/CIRCHEARTFAILURE.117.004311]

27 Selby DE, Palmer BM, LeWinter MM, Meyer M. Tachycardia-induced diastolic dysfunction and resting tone in cardiomyocytes from patients with a normal ejection fraction. *J Am Coll Cardiol* 2011; 58: 147-154 [PMID: 21718911 DOI: 10.1016/j.jacc.2010.10.069]

28 Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardimelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hensfus G, Jacobschagen C. RAno/Lane for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. *JACC Heart Fail* 2013; 1: 115-122 [PMID: 24621836 DOI: 10.1016/j.jchf.2012.12.002]

29 Borbély A, van der Velden J, Papp Z, Bronzwaer JG, Eides I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. *Circulation* 2005; 111: 774-781 [PMID: 15692624 DOI: 10.1161/01.CIR.0000155277.33485.6D]

30 Zile MR, Baico CF, Ikonomidis JS, Straw RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Ganzier HL, LeWinter MM. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. *Circulation* 2015; 131: 1247-1259 [PMID: 25637629 DOI: 10.1161/CIRCULATIONAHA.114.012125]

31 Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleczewski JJ, Packer M. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. *Circulation* 2015; 131: 550-559 [PMID: 25552356 DOI: 10.1161/CIRCULATIONAHA.114.009625]

32 Kapur NK. Transforming growth factor-β: governing the transition from inflammation to fibrosis in heart failure with preserved left ventricular function. *Circ Heart Fail* 2011; 4: 5-7 [PMID: 21245455 DOI: 10.1161/CIRCHEARTFAILURE.110.960054]

33 Schellert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. *J Am Coll Cardiol* 2014; 63: 2188-2198 [PMID: 24657693 DOI: 10.1016/j.jacc.2014.01.068]

34 Beale AL, Meyer P, Marwick TH, Lam CSP, Kaye DM. Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction. *Circulation* 2018; 138: 196-205 [PMID: 29986961 DOI: 10.1161/CIRCULATIONAHA.118.034271]

35 Zeng H, Chen JX. Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction. *Front Cardiovasc Med* 2019; 6: 15 [PMID: 30873415 DOI: 10.3389/fcmv.2019.00015]

36 Packer M. Derangements in adrenergic-adenopine signalling establishing a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction. *Eur J Heart Fail* 2018; 20: 873-878 [PMID: 29493068 DOI: 10.1002/ejhf.1167]

37 Martínez-Martínez E, Jurado-López R, Valero-Muñoz M, Bartolomé MV, Ballesteros S, Luaces M, Briones AM, López-Andrés N, Miana M, Cachofoño V. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. *J Hypertens* 2014; 32: 1104-11, discussion 1114 [PMID: 24095395 DOI: 10.1097/HJH.0000000000000169]

38 Tanaka S, Momose Y, Tsutsui S, Kishida T, Kuroda J, Shibata N, Yoshida T, Yamagishi R. Quantitative estimation of myocardial fibrosis based on receptor occupancy for beta2-adrenergic receptor agonists in rats. *J Toxicol Sci* 2004; 29: 179-186 [PMID: 15467267 DOI: 10.2111/jts.29.179]

39 Miura S, Suematsu Y, Matsuo Y, Tomita S, Nakayama A, Gotoda T, Arimura T, Kawano T, Yahiro E, Saku K. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a
human adrenocortical cell line. *Hypertens Res* 2016; 39: 758-763 [PMID: 27334058 DOI: 10.1038/hr.2016.72].

Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. *J Mol Cell Cardiol* 2000; 32: 865-879 [PMID: 10888242 DOI: 10.1006/jmcc.2000.1129].

Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol* 2017; 14: 591-602 [PMID: 28492288 DOI: 10.1038/nrcardio.2017.65].

Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. *Circulation* 2013; 128: 1085-1093 [PMID: 23908348 DOI: 10.1161/CIRCULATIONAHA.113.014757].

Iwanga Y, Nishi I, Furuchi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. *J Am Coll Cardiol* 2006; 47: 742-748 [PMID: 16487838 DOI: 10.1016/j.jacc.2005.11.030].

Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. *Am J Cardiol* 2008; 102: 733-737 [PMID: 18773998 DOI: 10.1016/j.amjcard.2008.04.048].

Zile MR, Baica CF. Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. *J Cardiovasc Transl Res* 2013; 6: 501-515 [PMID: 23761303 DOI: 10.1007/s12265-013-9472-1].

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filipatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Massoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Card Fail* 2017; 23: 628-651 [PMID: 28461259 DOI: 10.1016/j.cardfail.2017.04.014].

Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Ob JK, Poppeau BA, Waggner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016; 29: 277-314 [PMID: 27037982 DOI: 10.1016/j.echo.2016.01.011].

Mordi IR, Singh S, Rudd A, Srinivasan J, Frenneaux M, Tzemou N, Dawson KW. Comprehensive Echocardiographic and Cardiac Magnetic Resonance Evaluation Differentials for Preserved Ejection Fraction Patients, Hypertensive Patients, and Healthy Control Subjects. *JACC Cardiovasc Imaging* 2018; 11: 577-585 [PMID: 28823736 DOI: 10.1016/j.jcmg.2017.05.022].

Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leito-Moreira AF, Borbely A, Eides I, Handoko ML, van Boxtel P, Pescocostanzo B, Dickstein K, Fraser AG, Brutsea D. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. *Eur Heart J* 2007; 28: 2359-2367 [PMID: 17428622 DOI: 10.1093/eurheartj/ehm380].

Mitter SS, Shah SJ, Thomas JD. A Test in Context: E/A and E'/e' to Assess Diastolic Dysfunction and LV Filling Pressure. *J Am Coll Cardiol* 2017; 69: 1451-1464 [PMID: 28302294 DOI: 10.1016/j.jacc.2016.12.037].

Zile MR, Gottlieber JS, Heitzel SJ, McMurray JJ, Komajda M, McKeilvies R, Baica CF, Massie BM, Carson PE, I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. *Circulation* 2011; 124: 2491-2501 [PMID: 22064591 DOI: 10.1161/CIRCULATIONAHA.110.101031].

Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. *Circulation* 2018; 138: 861-870 [PMID: 29792299 DOI: 10.1161/CIRCULATIONAHA.118.034680].

Marschner J, Marzulli BA, Tufaro C, Pfaffenberger S, Graf A, Wesberg P, Panzenböck A, Jakowitsch J, Bangert C, Laimer D, Schreiber C, Karakus G, Hülsmann M, Pacher R, Lang IM, Maurer G, Bonderman D. Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. *Circ Cardiovasc Imaging* 2013; 6: 1056-1065 [PMID: 24063385 DOI: 10.1161/CIRCIMAGING.113.006233].

Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, Tseng WY. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. *JACC Cardiovascular Imaging* 2014; 7: 999-997 [PMID: 25204451 DOI: 10.1016/j.jcmg.2014.04.022].

Rommel KP, von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K, Besler C, Sandri M, Lücke C, Guthbert M, Linke A, Schuler G, Lurz P. Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction. *J Am Coll Cardiol* 2016; 67: 1815-1825 [PMID: 27081022 DOI: 10.1016/j.jacc.2016.02.018].

Schelbert EB, Fridman Y, Wong TC, Abu Daya H, Pfeiler KM, Kadakkal A, Miller CA, Uzan G, Manja M, Kellman P, Sha J, Abebe KZ, Simon MA, Quarta G, Senni M, Butler J, Dame J, Redfield MM, Gheorghiade M. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. *JAMA Cardiol* 2017; 2: 995-1006 [PMID: 28768311 DOI: 10.1001/jamacardio.2017.2511].

Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. *Circ Heart Fail* 2010; 3: 588-595 [PMID: 20451734 DOI: 10.1161/CIRCHARTFAILURE.109.93070].

Nanayakkara S, Haykowsky M, Mariani J, Van Empel V, Maeder MT, Vizi D, Kaye DM. Hemodynamic Profile of Patients With Heart Failure and Preserved Ejection Fraction Vary by Age. *J Am Heart Assoc* 2017; 6 [PMID: 28093710 DOI: 10.1016/j.jaha.2016.05.034].

Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. *J Am Coll Cardiol* 2011; 58: 265-274 [PMID: 21737017 DOI: 10.1016/j.jacc.2011.02.055].

Trevisan L, Cautela J, Ressegueir N, Laine M, Arques S, Pinto J, Oribone M, Barraud J, Peyrol M, Paganelli F, Bonello L, Thuny F. Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: A systematic angiography approach. *Arch Cardiovasc Dis* 2018; 111: 109-118 [PMID: 29031580 DOI: 10.1016/j.acvd.2017.05.006].
Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects of carvedilol on heart failure with preserved systolic function. *Am J Cardiol* 2002; 89: 719-722 [PMID: 11897215 DOI: 10.1016/S0002-9149(01)02345-1]

Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. *Circ Res* 2019; 124: 1598-1617 [PMID: 31120821 DOI: 10.1161/CIRCRESAHA.119.313572]

Hwang SJ, Meloenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2014; 63: 2817-2827 [PMID: 24768876 DOI: 10.1016/j.jacc.2014.03.034]

Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundleby G, Kraus WE, Eggebeen J, Nicklas BJ. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. *JAMA* 2016; 315: 36-46 [PMID: 26746456 DOI: 10.1001/jama.2015.17346]

Chan E, Giallauria F, Vigorito C, Smart NA. Exercise training in heart failure patients with preserved ejection fraction: a systematic review and meta-analysis. *Monaldi Arch Chest Dis* 2016; 86: 759 [PMID: 27748473 DOI: 10.4081/monaldi.2016.759]

Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J, Kitzman DW. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. *J Am Coll Cardiol* 2012; 60: 120-128 [PMID: 22766338 DOI: 10.1016/j.jacc.2012.02.055]

Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. *Eur Heart J* 2012; 33: 1750-1757 [PMID: 21821849 DOI: 10.1093/eurheartj/ehs254]

Ettched JD, Endin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet* 2016; 387: 957-967 [PMID: 26724178 DOI: 10.1016/S0140-6736(15)02225-8]

Collicott PE. 1991: an "intense" year for the house of medicine. *Nehr Med J* 1991; 76: 17-19

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand JS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfeld JL, Shabirshivili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014; 370: 1383-1392 [PMID: 24716680 DOI: 10.1056/NEJMoa1313731]

Gu J, Fan YQ, Han ZH, Fan L, Bian L, Zhang HL, Xu ZJ, Yin ZF, Xie YS, Zhang JF, Wang CQ. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients. *Int J Cardiol* 2016; 220: 56-60 [PMID: 27372043 DOI: 10.1016/j.ijcard.2016.08.190]

Gu J, Fan YQ, Bian L, Zhang JHL, Xu ZJ, Zhang Y, Chen QZ, Yin ZF, Xie YS, Wang CQ. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study. *Eur J Prev Cardiol* 2016; 23: 1421-1425 [PMID: 26915580 DOI: 10.1177/2047487316632660]

Kotecha D, Lans CM, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. *J Am Coll Cardiol* 2016; 68: 2217-2228 [PMID: 27858111 DOI: 10.1016/j.jacc.2016.08.048]

Lam CS, Rienstra M, Tay WT, Liu LC, Hummel YM, van der Meer P, de Boer RA, Van Gelder IC, Van Veldhuisen DJ, Voors AA, Hoedemakers ES. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. *J Am Coll Cardiol* 2017; 5: 92-98 [PMID: 28055570 DOI: 10.1016/j.jacc.2016.10.005]

Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyes L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. *Eur J Heart Fail* 2009; 11: 676-683 [PMID: 19553398 DOI: 10.1093/eurjhf/hfp685]

Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chowienczyk P, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019; 21: 1169-1186 [PMID: 31200293 DOI: 10.1002/ejhf.1537]

Machino-Ohtsuka T, Sato Y, Ishizu T, Sugano A, Atsumi A, Yamamoto M, Kawamura R, Machino T, Kuroki K, Yamashiki H, Ishigaki M, Sekiguchi Y, Aonuma K. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2013; 62: 1857-1865 [PMID: 23916940 DOI: 10.1016/j.jacc.2013.07.020]

Zisman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mathieu M, Devis T, Johansen OH, Woerle HJ, Broedel UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, in Patients With Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 2015; 372: 2117-2128 [PMID: 26387439 DOI: 10.1056/NEJMoa1504720]

Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Bruckmeyer M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McColough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Wanner C, Woerle HJ, Broedl UC, Inzucchi SE; EMPEROR-Reduced Investigators. Empagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, in Patients With Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 2018; 378: 920-930 [PMID: 29557071 DOI: 10.1056/NEJMoa1710938]

Krittanawong C, Kuhn ML. Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a contemporary Review. *Curr Treat Options Cardiovasc Med* 2018; 20: 28 [PMID: 29557071 DOI: 10.1007/s11936-018-0623-1]

Lund LH, Benson L, Dahlström U, Edner M, Friberg L. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. *JAMA* 2014; 312: 2008-2018 [PMID: 25399226 DOI: 10.1001/jama.2014.15241]

Bergström A, Anderson B, Edner M, Nylander E, Persson H, Dahlström U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDEC). *Eur J Heart Fail* 2004; 6: 453-461 [PMID: 15182771 DOI: 10.1016/j.ejheart.2004.02.003]

Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects of carvedilol on heart failure with preserved systolic function. *Am J Cardiol* 2002; 89: 719-722 [PMID: 11897215 DOI: 10.1016/S0002-9149(01)02345-1]
Henning RJ. HFpEF diagnosis and treatment

preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110-118 [PMID: 22983988 DOI: 10.1093/eurjhf/hfs141]

84 Massie BM, Nelson JJ, Lukas MA, Greenberg B, Fowler MB, Gilbert EM, Abraham WT, Lottes SR, Franciosa JA; COHERE Participant Physicians. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol 2007; 99: 1263-1268 [PMID: 17478155 DOI: 10.1016/j.amjcard.2006.12.056]

85 Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinewine L, Tornam, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized, double-blind, placebo-controlled trial of nebivolol on mortality and cardiorespiratory hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225 [PMID: 15642700 DOI: 10.1093/eurheartj/ehu151]

86 van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babahls D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: a randomized trial. Eur J Heart Fail 2009; 11: 73-79 [PMID: 19130987 DOI: 10.1093/eurjhf/hfp193]

87 Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas PE, Böhm M, Dei Cas L. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012; 14: 219-225 [PMID: 22147202 DOI: 10.1093/eurjhf/hfr161]

88 Edelman F, Mustal-Bright L, Gelbrich G, Trippel T, Radenovic S, Wachter R, Inkrot S, Loncar G, Tahirovic E, Celic V, Veskovic J, Zdravkovic M, Lainscak M, Apostolovic S, Neskov AC, Pieske B, Dühning HD; CIBIS-ELD Investigators and Project Multicenter Trials in the Competence Network Heart Failure. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From The CIBIS-ELD Trial. JACC Heart Fail 2016; 4: 140-149 [PMID: 26682793 DOI: 10.1016/j.jchf.2015.10.008]

89 El-Refa1 M, Peterson EL, Wells K, Swadia T, Sabbath BN, Spterus JA, Williams AK, Lanfear DE. Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail 2013; 19: 73-79 [PMID: 23384631 DOI: 10.1016/j.cardfail.2012.11.011]

90 Zhou J, Shi H, Zhang J, Lu Y, Fu M, Ge J; beta-PRESERVE Study Investigators. Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. Eur J Heart Fail 2010; 12: 181-185 [PMID: 20883623 DOI: 10.1002/ejhf.193]

91 Hernandez AF, Hammill RG, O'Connor CM, Schulman KA, Curtis LH, Farnsworth GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. Am J Cardiol 2009; 53: 184-192 [PMID: 19130987 DOI: 10.1093/eurheartj/ehx093]

92 Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66: 981-986 [PMID: 2220622 DOI: 10.1016/0002-9149(90)90376-C]

93 Hung MJ, Cheng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002; 56: 57-62 [PMID: 11831835]

94 Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71: 602-604 [PMID: 8438750 DOI: 10.1016/0002-9149(93)90520-M]

95 Cléland JG, Tendera M, Adams J, Freeman R,Boot R, Ley M, O'Mahony D, Polomski L, Taylor J. Pandeopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP-CHF study group. Eur J Heart Fail 1999; 1: 211-217 [PMID: 10935667 DOI: 10.1016/S1388-9842(99)00039-2]

96 Massie BM, Carson PE, McMurray JJ, Komajda M, McKeilvire R, Zile M, Anderson S, Donovan M, Ivenson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2009; 359: 2456-2467 [PMID: 19001508 DOI: 10.1056/NEJMoa0903540]

97 Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2007; 363: 773-781 [PMID: 15678871 DOI: 10.1016/S0140-6736(07)61080-7]

98 Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraaiker-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Letkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management of Heart failure/re with preserved ejection fraction (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395 [PMID: 22932717 DOI: 10.1016/S0140-6736(12)6227-6]

99 Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of Ij-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 2013; 62: 1330-1338 [PMID: 23916925 DOI: 10.1016/j.jacc.2013.06.043]

100 Komajda M, Istand R, Cohensolal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjın F, Henon-Goburdhun C, Pannaux M, Böhm M; pReservedL left ventricular ejection fraction chronic heart Failure with ivabradine study (EDIFY) Investigators. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 2017; 19: 1495-1503 [PMID: 28462319 DOI: 10.1002/ejhf.876]

101 Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112: 357-363 [PMID: 16090792 DOI: 10.1161/CIRCULATIONAHA.104.119876]

102 Onouzian M, Tu JV, Austin PC, Chong A, Liu PP, Lee DS. Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. J Card Fail 2009; 15: 241-248 [PMID: 19327626 DOI: 10.1016/j.cardfail.2008.10.026]

103 Gómez-Barre D, Gonzalez-Rubio ML, Muñoz-Pacheco P, Caro-Vadillo A, Aragoncillo P, Fernández-Cruz A. Rosuvastatin added to standard heart failure therapy improves cardiac remodeling in heart failure rats with preserved ejection fraction. Eur J Heart Fail 2010; 12: 903-912 [PMID: 20601374 DOI: 10.1093/eurjhf/hfp101]
Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digoxin investigation group trial. *Circulation* 2006; 114: 397-403 [PMID: 16864724 DOI: 10.1161/CIRCULATIONAHA.106.628347]

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA* 2013; 309: 1268-1277 [PMID: 23478662 DOI: 10.1001/jama.2013.2024]

Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E; NHLBI Heart Failure Clinical Research Network. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. *N Engl J Med* 2015; 373: 2314-2324 [PMID: 26549714 DOI: 10.1056/NEJMoa1510774]

Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM, Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith AL, Tang WH, Wehlayan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P, Hernandez AF, Braunwald E, Redfield MM; National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. *JAMA* 2018; 320: 1764-1773 [PMID: 30398602 DOI: 10.1001/jama.2018.14652]

Borlaug BA, Melenovsky V, Koepp KE. Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. *Circ Res* 2016; 119: 880-886 [PMID: 27458234 DOI: 10.1161/CIRCRESAHA.116.309184]

Feldman T, Mauri L, Kahwashi R, Litwin S, Ricciardi MJ, van der Harst P, Penicka M, Fail PS, Kaye DM, Ketrie MC, Basavaraj A, Hummel SL, Forde-McLean R, Nielsen CD, Lilly S, Massaro JM, Burkhoff D, Shah SJ, REDUCE LAP-HF Investigators and Study Coordinators. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. *Circulation* 2018; 137: 364-375 [PMID: 29142012 DOI: 10.1016/j.circRES.2017.03.009]

Feldman T. A Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure With Preserved or Mid-Range Ejection Fraction (REDUCE LAP-HF I): 1-Year Results from the Phase 2, Randomized, Blinded, Sham-Controlled Trial. Paper presented at: The European Society of Cardiology; 2018; Aug 27; Munich, Germany

Adamson PB, Abrahm WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, Henderson J, Cowart P, Stevenson LW. Wireless pulmonary artery pressure monitoring guides management to reduce decomposition in heart failure with preserved ejection fraction. *Circ Heart Fail* 2014; 7: 935-944 [PMID: 25286913 DOI: 10.1161/CIRCEHARTFAILURE.113.001229]

Burkhoff D, Maurer MS, Joseph SM, Rogers JG, Birati EY, Ramje EE, Shah SJ. Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations. *JACC Heart Fail* 2015; 3: 275-282 [PMID: 25770409 DOI: 10.1016/j.jchf.2014.10.011]

van der Meer P, Gaggin HK, Dev CW. ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. *J Am Coll Cardiol* 2019; 73: 2756-2768 [PMID: 31146820 DOI: 10.1016/j.jacc.2019.03.478]
